AKT1 and melanoma: Even at low doses, celecoxib demonstrated an adjuvant potential in melanoma co-culture after preventing phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) activation, reducing melanogenesis, and promoting apoptosis.